|

ONC-783 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Bispecific antibody against CD24 and CD3

Pipeline

Phase 1: 1

Top Sponsors

  • OncoC4, Inc.1

Indications

New York, New York1 trial

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

Columbia University Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.